PPARD and Duchenne muscular dystrophy: The PPARδ selective agonist ASP0367 has shown a good safety profile in healthy voluntaries and has entered a clinical trial to test its effectiveness in boys with DMD, but unfortunately this study was terminated early due to enrollment challenges.